Bone mineral density in young women with primary ovarian insufficiency: Results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages 3418-3426

  Popat, Vaishali B ^a   Calis, Karim A ^b   Kalantaridou, Sophia N ^a   Vanderhoof, Vien H ^a   Koziol, Deloris ^c   Troendle, James F ^c   Reynolds, James C ^d   Nelson, Lawrence M ^a  

^a Eunice Kennedy Shriver National Institute of Child Health and Human Development   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; PLACEBO; TESTOSTERONE; CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EDUCATIONAL STATUS; ESTRADIOL BLOOD LEVEL; FEMALE; FEMUR NECK; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; IMMUNOLOGY TEST KIT; KARYOTYPE 46,XX; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENARCHE; MICROPARTICLE ENZYME IMMUNOASSAY; OILY SKIN; OVARY INSUFFICIENCY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN IRRITATION; SKIN REDNESS; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; X RAY BONE DENSITOMETER; 46, XX DISORDERS OF SEX DEVELOPMENT; BLOOD; DRUG COMBINATION; DRUG EFFECTS; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; PHOTON ABSORPTIOMETRY; PRIMARY OVARIAN INSUFFICIENCY; PROCEDURES; RADIOGRAPHY; THERAPY; YOUNG ADULT;

46, XX DISORDERS OF SEX DEVELOPMENT; ABSORPTIOMETRY, PHOTON; ADMINISTRATION, CUTANEOUS; ADULT; BONE DENSITY; CONTRACEPTIVE AGENTS, FEMALE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; FEMUR NECK; HORMONE REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE ACETATE; PRIMARY OVARIAN INSUFFICIENCY; PROSPECTIVE STUDIES; TESTOSTERONE; THERAPEUTICS; YOUNG ADULT;

EID: 84907193694     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4145     Document Type: Article

References (37)

1. Lewiecki EM. In the clinic. Osteoporosis. Ann Intern Med 2011; 155(1): ITC1-15.
2. Popat VB, Calis KA, Vanderhoof VH, et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab. 2009; 94(7): 2277-2283.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3): 321-333.
4. Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in youngwomentreated with luteinizing hormonereleasing hormone agonists? J Clin Endocrinol Metab. 1990;70(4): 920-924.
5. Metka M, Holzer G, Heytmanek G, Huber J. Hypergonadotropic hypogonadic amenorrhea (World Health Organization III) and osteoporosis. Fertil Steril. 1992;57(1): 37-41.
6. Leather AT, Studd JW, Watson NR, Holland EF. The prevention of bone loss in young women treated withGnRHanalogues with "addback" estrogen therapy. Obstet Gynecol. 1993;81(1): 104-107.
7. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol. 1993;168(1 Pt 1): 114-121.
8. Castelo-Branco C, Rovira M, Pons F, et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas. 1996;23(3): 307-312.
9. Grinspoon SK, Friedman AJ, Miller KK, Lippman J, Olson WH, Warren MP. Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea. J Clin Endocrinol Metab. 2003;88(8): 3651-3656.
10. Gulekli B, DaviesMC,Jacobs HS. Effect of treatment on established osteoporosis in young women with amenorrhoea. Clin Endocrinol (Oxf). 1994;41(3): 275-281.
11. Cohen A, Fleischer J, Freeby MJ, McMahon DJ, Irani D, Shane E. Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center. J Womens Health (Larchmt ). 2009; 18(1): 79-84.
12. Albright F, Smith PH, Fraser R. A syndrome characterized by primary ovarian insufficiency and decreased stature. Am J Med Sci. 1942;204(5): 625-648.
13. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67: 604-606.
14. Kalantaridou SN, Calis KA, Vanderhoof VH, et al. Testosterone deficiency in young women with 46,XX spontaneous premature ovarian failure. Fertil Steril. 2006;86(5): 1475-1482.
15. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995;21(3): 227-236.
16. Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC. Sex steroids, bone mass, and bone loss.Aprospective study of pre-, peri-, and postmenopausal women. J Clin Invest. 1996;97(1): 14-21.
17. Khosla S, Melton LJ III, Atkinson EJ, O'FallonWM,Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83(7): 2266-2274.
18. Anasti JN, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol. 1998;91: 12-15.
19. Popat VB, Vanderhoof VH, Calis KA, Troendle JF, Nelson LM. Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency. Fertil Steril. 2008;89(2): 429-433.
20. Southren AL, Gordon GG, Tochimoto S. Further study of factors affecting the metabolic clearance rate of testosterone in man. J Clin Endocrinol Metab. 1968;28(8): 1105-1112.
21. Abraham GE, Lobotsky J, Lloyd CW. Metabolism of testosterone and androstenedione in normal and ovariectomized women. J Clin Invest. 1969;48(4): 696-703.
22. Nelson LM. Primary ovarian insufficiency. N Engl J Med. 2009; 360(6): 606-614.
23. Kalantaridou SN, Calis KA, Mazer NA, Godoy H, Nelson LM. A pilot study of an investigational testosterone transdermal patch system in young women with spontaneous premature ovarian failure. J Clin Endocrinol Metab 2005;90(12): 6549-6552.
24. Consensus Development Conference: Diagnosis, Prophylaxis, and Treatment of Osteoporosis. Am J Med 1993;94: 646-650.
25. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21: 1440-1447.
26. Tagatz GE, Kopher RA, Nagel TC, Okagaki T. The clitoral index: a Bioassay of androgenic stimulation. Obstet Gynecol. 1979;54(5): 562-564.
27. Cremoncini C, Vignati E, Libroia A. Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol. Acta Eur Fertil. 1976;7(4): 299-314.
28. Bonnick SL, Johnston CC Jr, Kleerekoper M, et al. Importance of precision in bone density measurements. J Clin Densitom. 2001; 4(2): 105-110.
29. Nelson JC, Tomei RT. Direct determination of free thyroxine in undiluted serum by equilibrium dialysis/radioimmunoassay. Clin Chem. 1988;34(9): 1737-1744.
30. Scarabin PY, Henc-Gelas M, Plu-Bureau, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women.A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997; 17(11): 3071-3078.
31. Scarabin PY, Oger E, Plu-Bureau. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362(9382): 428-432.
32. Canonico M, Oger E, Plu-Bureau, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: theESTHER study. Circulation. 2007;115(7): 840-845.
33. Mishell DR Jr, Nakamura RM, Crosignani PG, et al. Serum gonadotropin and steroid patterns during the normal menstrual cycle. Am J Obstet Gynecol. 1971;111(1): 60-65.
34. Crofton PM, Evans N, Bath LE, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol (Oxf). 2010;73(6): 707-714.
35. Rochira V, Zirilli L, Madeo B, et al. Skeletal effects of long-Term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone. Bone. 2007;40(6): 1662-1668.
36. Misra M, Katzman D, Miller KK, et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res. 2011;26(10): 2430-2438.
37. Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab. 1995; 80(3): 898-904.